Avinger Inc is a United States-based company. The Company operates as a medical device company that designs, manufactures, and sells image-guided, catheter-based systems for treating peripheral artery disease (PAD). Its products are used by interventional cardiologists, vascular surgeons, and interventional radiologists in the United States and select international markets and are based on its Lumivascular platform, a system that uses optical coherence tomography (OCT) for real-time visualization inside arteries. Its products includes the Lightbox imaging console, Ocelot and Tigereye catheters for crossing blockages, and Pantheris for removing plaque.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

19/02/25	Avinger, Inc.(NasdaqCM:AVGR) dropped from S&P TMI Index	CI
16/02/25	Avinger, Inc.(NasdaqCM:AVGR) dropped from NASDAQ Composite Index	CI

Market Cap	2.71M 2.34M 2.15M 2.02M 3.78M 257M 3.84M 25.44M 9.92M 125M 10.16M 9.94M 434M	P/E Ratio 2022	-0.25x	P/E Ratio 2023	-0.19x
Enterprise Value	12.83M 11.08M 10.21M 9.56M 17.91M 1.22B 18.19M 121M 47M 593M 48.14M 47.12M 2.05B	EV / Sales 2022	1.19x	EV / Sales 2023	1.78x
Free-Float	88.44%	Yield 2022 *	-	Yield 2023	-

19/02/25	Avinger, Inc.(NasdaqCM:AVGR) dropped from S&P TMI Index	CI
16/02/25	Avinger, Inc.(NasdaqCM:AVGR) dropped from NASDAQ Composite Index	CI
10/02/25	Avinger Inc Terminated Employment Of Each Of Jeffrey M. Soinski, Co's CEO And Nabeel Subainati, Vice President, Finance	RE
10/02/25	Avinger, Inc. Announces Termination of the Employment of Jeffrey M. Soinski, Chief Executive Officer	CI
10/02/25	Avinger, Inc. Announces Executive Changes	CI
24/12/24	Wall Street Set to Open Mixed Tuesday Ahead of Holiday Break	MT
24/12/24	US Futures Tread Water Ahead of Holiday Break	MT
23/12/24	Iberdrola Completes Merger with Avangrid	MT
07/11/24	Avinger, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
07/11/24	Earnings Flash (AVGR) AVINGER Reports Q3 Loss $-1.82	MT
07/11/24	Earnings Flash (AVGR) AVINGER Posts Q3 Revenue $1.7M	MT
07/11/24	Avinger, Inc., Q3 2024 Earnings Call, Nov 07, 2024
04/10/24	Wall Street Set to Open Higher Friday on Strong Employment Data	MT

21/04/23	HC Wainwright Starts Avinger at Buy With $1.60 Price Target	MT
11/05/22	B. Riley Lowers Avinger's Price Target to $9 from $11, Keeps Buy Rating	MT
18/03/22	B. Riley Adjusts Avinger's Price Target to Post-Split $11 from $40, Expects Omicron Impact Late in Q4, Into Q1; Keeps Buy Rating	MT
29/06/21	AVINGER : B. Riley Starts Avinger at Buy with $2.50 PT, Says Well-Positioned to Execute on Growth Strategy	MT

02/01/25	Avinger : Private Placement Form 8 K	PU
08/11/24	Avinger : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
08/11/24	Avinger : Reports Third Quarter 2024 Results Form 8 K	PU
07/11/24	Avinger: Q3 Earnings Snapshot	AQ
25/10/24	Avinger Releases Updated Data from IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention	AQ

AVINGER Share Price Nasdaq

Stocks

Advanced Medical Equipment & Technology

Valuation: AVINGER

Latest news : AVINGER

Analysts' recommendations: AVINGER

Press Releases: AVINGER

Managers and Directors: AVINGER

Medical Imaging Systems

Financials

Company Profile

Manager	Title	Age	Since
Karina Yamamoto CEO	Chief Executive Officer	-	-
Thomas Davis CTO	Chief Tech/Sci/R&D Officer	-	04/08/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.	+1.60%	+0.92%	-11.95%	-16.85%	13.82B
IRAY GROUP	-5.68%	-9.58%	+76.48%	+11.82%	4.89B
SONOSCAPE MEDICAL CORP.	+3.68%	-1.60%	-38.95%	-64.79%	1.25B
BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.	+1.85%	-6.01%	-33.54%	-43.06%	1.2B
IRADIMED CORPORATION	-2.76%	+0.57%	+60.91%	+90.24%	1.2B
SHANTOU INSTITUTE OF ULTRASONIC INSTRUMENT CO., LTD.	+5.99%	-0.89%	-40.57%	-	985M
CARERAY DIGITAL MEDICAL TECHNOLOGY CO., LTD.	+0.47%	-5.38%	+192.61%	+183.63%	716M
CAPSOVISION, INC.	+4.35%	0.00%	-	-	359M
FISCHER MEDICAL VENTURES LIMITED	-1.30%	+11.03%	-59.11%	+207.35%	247M
Average	+0.91%	+0.32%	+18.23%	+52.62%	2.74B
Weighted average by Cap.	+0.22%	-1.25%	+11.36%	-0.74%

	2022	2023
Net sales	8.27M 7.15M 6.58M 6.16M 11.55M 786M 11.73M 77.75M 30.31M 383M 31.05M 30.39M 1.33B	7.65M 6.61M 6.09M 5.7M 10.68M 727M 10.85M 71.91M 28.04M 354M 28.72M 28.11M 1.23B
Net income	-17.62M -15.22M -14.03M -13.13M -24.6M -1.68B -24.99M -166M -64.57M -815M -66.14M -64.73M -2.82B	-18.32M -15.82M -14.58M -13.65M -25.58M -1.74B -25.97M -172M -67.13M -848M -68.75M -67.29M -2.93B
Net Debt	1.76M 1.52M 1.4M 1.31M 2.45M 167M 2.49M 16.5M 6.43M 81.24M 6.59M 6.45M 281M	10.12M 8.74M 8.05M 7.54M 14.13M 962M 14.35M 95.11M 37.08M 468M 37.98M 37.17M 1.62B

End-of-day quote Nasdaq Other stock markets
- ^USD	-